iiinova — where your digital self keeps evolving

Yi David Ju @davidyiju.bsky.social · 02/07/2026

Excited that our paper, “Blood Distribution of SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine in Humans”, is a finalist for the 2026 ACS Nano Impact Award. This work provides new insights into human LNP-mRNA vaccine biodistribution. Read our paper here: pubs.acs.org/doi/10.1021/...

000

Reposted by Yi David Ju

ONJ Cancer Research Institute @onjcri.org.au · 01/07/2026

New review paper by the NGTL published in Advanced Drug Delivery Reviews. • Brings together current knowledge on anti-PEG Abs • Discusses ways to reduce immune system interference • Highlights that anti-PEG Abs could be leveraged to develop new cancer therapies ➡️ ow.ly/hNYc50ZiZoP

101

Reposted by Yi David Ju

medRxivpreprint @medrxivpreprint.bsky.social · 16/03/2026

In Vivo Blood Kinetics and Transcript Integrity of Three mRNA-Lipid Nanoparticle Vaccines in Humans www.medrxiv.org/content/10.64898/20…

001

Yi David Ju @davidyiju.bsky.social · 31/12/2025

2026 Happy New Year, everyone!

010

Reposted by Yi David Ju

ONJ Cancer Research Institute @onjcri.org.au · 26/10/2025

Catch ONJCRI’s Dr Pavitha Parathan and Dr @davidyiju.bsky.social on @drshanerrr.bsky.social’s RRR program, Einstein A Go-Go this morning 📻 Talking bowel cancer and novel cancer treatment delivery systems 🔬 #sciencemedia #cancerresearch

121

Reposted by Yi David Ju

ONJ Cancer Research Institute @onjcri.org.au · 25/09/2025

ONJCRI researchers and collaborators at @unimelb.bsky.social and RMIT have developed a novel nanomedicine delivery system with highly ordered structures that enhance cargo delivery to their targets. ➡️ Read the paper: ow.ly/XmYX50X1j4I #LipidNanoparticles #Nanomedicine #CancerResearch

031

Yi David Ju @davidyiju.bsky.social · 14/06/2025

Excited to serve as a discussion leader this afternoon at the Cancer Nanotechnology Gordon Research Seminar in Italy! Looking forward to a great session of talks and discussion. www.grc.org/cancer-nanot... #GRC #CancerNanomedicine

grc.org

2025 Cancer Nanotechnology (GRS) Seminar GRC

The 2025 Gordon Research Seminar on Cancer Nanotechnology (GRS) will be held in Lucca (Barga), Lucca Italy. Apply today to reserve your spot.

010

Reposted by Yi David Ju

ONJ Cancer Research Institute @onjcri.org.au · 03/06/2025

📚 Congratulations to Dr Yi (David) Ju who received the Editorial Contribution Award and Author Service Award from ‪@springernature.com‬. These awards are a recognition of Dr Ju's contributions as an Editor for the Journal of Materials Science. #ONJCRI #ScientificJournal

021

Yi David Ju @davidyiju.bsky.social · 23/05/2025

Thrilled to see our Comment, “Balancing stealth and targeting to improve nanomedicine efficacy”, featured in the latest Nature Nanotechnology Editorial on PEGylation in nanomedicine. 📝 doi.org/10.1038/s415... 🗞️ doi.org/10.1038/s415...

doi.org

The benefits and risks of PEGylation in nanomedicine - Nature Nanotechnology

Polyethylene glycol (PEG) is a commonly used coating agent in nanomedicine, but there are growing concerns about its immunogenicity. Two Comment articles discuss the issue and possible alternatives to...

010

Yi David Ju @davidyiju.bsky.social · 19/05/2025

Registration via CRS website: crs.site-ym.com/Login.aspx?o... CRS Page: www.controlledreleasesociety.org/events/lc-we...

000

Yi David Ju @davidyiju.bsky.social · 19/05/2025

Excited to speak at the Controlled Release Society (CRS) Local Chapter webinar on 21 May! ⏰ 8-10 AM UTC | 10 AM-12 PM CET | 6-8 PM AEST. My talk: From fundamental bio-nano interactions to mRNA vaccines & therapeutics. Free to join 👉Zoom Link: us06web.zoom.us/j/81945385019 Meeting ID: 819 4538 5019

111

Yi David Ju @davidyiju.bsky.social · 14/05/2025

📄 Thrilled! First paper from our new Nanomedicine & Gene Therapeutics Lab @onjcri.org.au just dropped in Nature Nanotechnology. We unpack the #stealth vs #targeting trade‑off—keeping nanoparticles invisible to immunity yet laser‑guiding them to diseased cells.

onjcri.org.au

Harnessing nanotechnology to advance drug and gene delivery - Olivia Newton John Cancer Research Institute

Explore the study opportunity to harness nanotechnology in advancing drug and gene delivery, contributing to breakthrough cancer therapies.

120

Yi David Ju @davidyiju.bsky.social · 24/02/2025

I'm thrilled to share that I have received an National Health and Medical Research Council (NHMRC) Investigator Grant! This fellowship will support me in developing next-generation mRNA therapeutics for cancer over the next five years. Thank you to everyone who has supported me on this journey!

050

Reposted by Yi David Ju

ONJ Cancer Research Institute @onjcri.org.au · 19/02/2025

⭐ ONJCRI is thrilled to welcome @davidyiju.bsky.social and the Nanomedicine & Gene Therapeutics Laboratory, a new hub for pioneering cancer research focusing on delivering mRNA therapeutics using advanced nanotechnology. 🧬 Read more about Dr Ju's Lab: ow.ly/i9l350UZ5ie

062

Yi David Ju @davidyiju.bsky.social · 31/01/2025

Today is my last day at RMIT—a heartfelt thank you to my mentors, colleagues, students, and friends for your support and collaboration. Excited to start as a Lab Head @onjcri.org.au next week, advancing cancer research. Looking forward to staying connected!

010

Yi David Ju @davidyiju.bsky.social · 09/01/2025

Thank you to the RMIT Media Team for promoting our research! It is exciting to see our work featured in over 60 news outlets, including US TV news (WGN in Chicago), MSN, Yahoo News, NetEase News and AOL, reaching a total audience of 86 million people. Read the story: www.rmit.edu.au/news/all-new...

rmit.edu.au

Blood test could make cancer treatments safer and more effective

Scientists have developed a new blood test that could screen cancer patients to help make their treatment safer and more effective.

000

Yi David Ju @davidyiju.bsky.social · 08/01/2025

I’m excited to share that I was recently interviewed on 2GB’s “Healthy Living” program, where I discussed our team’s latest research on person-specific nanomedicine targeting leukemia. 🎧 Listen to the full interview broadcast.meltwater.com/public-api/s...

broadcast.meltwater.com

Broadcast player

000